With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Clinical Trials Arena on MSN1d
Amgen’s gMG therapy cuts disease symptoms at one-year markResults from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Uplizna is currently approved in the U.S ... and Argenx (ARGX), which market a treatment for generalized myasthenia gravis ...
Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...
Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback